<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Small transformed cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (STC) is the least common follicular center cell <z:hpo ids='HP_0002664'>neoplasm</z:hpo> in the Lukes-Collins classification system </plain></SENT>
<SENT sid="1" pm="."><plain>If the cells are homogenous in size and shape, Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (STC-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) is diagnosed; otherwise STC <z:hpo ids='HP_0002665'>lymphoma</z:hpo> of the non-Burkitt's type (STC-nBL) is present </plain></SENT>
<SENT sid="2" pm="."><plain>The authors have reviewed their experience with 17 cases of STC-nBL </plain></SENT>
<SENT sid="3" pm="."><plain>This <z:hpo ids='HP_0002664'>neoplasm</z:hpo> affects <z:hpo ids='HP_0000001'>all</z:hpo> ages, both sexes equally, and most commonly is Stage IV based either on a visceral abdominal mass or bone marrow involvement </plain></SENT>
<SENT sid="4" pm="."><plain>Surface immunoglobulin analysis revealed IgM in <z:hpo ids='HP_0000001'>all</z:hpo> cases tested </plain></SENT>
<SENT sid="5" pm="."><plain>In spite of aggressive treatment protocols, there were only 5 of 17 (29%) clinical complete responses </plain></SENT>
<SENT sid="6" pm="."><plain>Four of these five have continuous remission from 8 to 23 months after diagnosis; <z:hpo ids='HP_0000001'>all</z:hpo> four of these patients were treated with regimens containing high-dose <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>Future analyses including <z:mp ids='MP_0001799'>viral</z:mp> studies, chromosomal analyses, and uniform treatment protocols will help determine whether STC-nBL and Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> are truly distinct entities </plain></SENT>
</text></document>